Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 9/20 | 0.38 |
| ▸ | WNT3A | P56704 | 8/20 | 0.38 |
| ▸ | SPR | P35270 | 4/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 2/20 | 0.32 |
| ▸ | GUSB | P08236 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031316 | 0.87 | ALDH1A1 (0.41) | KDM4EHPGDALDH1A1TSHRHSD17B10 | |
| SCHEMBL1032348 | 0.85 | TNKS2 (0.46) | TNKS2WNT3ASPRTNKS | |
| SCHEMBL1034949 | 0.81 | TNKS2 (0.56) | HPGDALDH1A1TSHRTNKS2WNT3A | |
| SCHEMBL1036351 | 0.79 | SPR (0.40) | HPGDALDH1A1TSHRTNKS2WNT3A | |
| SCHEMBL8262657 | 0.78 | TNKS2 (0.45) | TNKS2WNT3ASPRTNKS | |
| SCHEMBL1034670 | 0.77 | SPR (0.40) | TNKS2WNT3ASPRAKR1C3TNKS | |
| SCHEMBL1031426 | 0.76 | HPGD (0.58) | KDM4EHPGDALDH1A1TSHRHSD17B10 | |
| SCHEMBL1031484 | 0.75 | PRMT5 (0.45) | TNKS2WNT3A | |
| SCHEMBL12342902 | 0.74 | HPGD (0.51) | KDM4EHPGDALDH1A1TSHRTNKS2 | |
| SCHEMBL1036534 | 0.74 | HPGD (0.71) | KDM4EHPGDALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268845-B2 | Tetrahydro- and dihydroquinazolinones | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | claimed |
| US-20110195965-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | FINSINGER DIRK | 2011-08-11 | — | — | US | claimed |
| EP-1856061-B1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | MERCK PATENT GMBH (DE) | 2011-01-26 | — | — | EP | claimed |
| US-20090318444-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | MERCK PATENT GMBH (DE) | 2009-12-24 | — | — | US | claimed |
| US-8268845-B2 | Tetrahydro- and dihydroquinazolinones | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268845-B2 | Tetrahydro- and dihydroquinazolinones | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268845-B2 | Tetrahydro- and dihydroquinazolinones | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20110195965-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | FINSINGER DIRK | 2011-08-11 | — | — | US | disclosed |
| US-20110195965-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | FINSINGER DIRK | 2011-08-11 | — | — | US | disclosed |
| US-20110195965-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | FINSINGER DIRK | 2011-08-11 | — | — | US | disclosed |
| EP-1856061-B1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | MERCK PATENT GMBH (DE) | 2011-01-26 | — | — | EP | disclosed |
| EP-1856061-B1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | MERCK PATENT GMBH (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-20090318444-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | MERCK PATENT GMBH (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318444-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | MERCK PATENT GMBH (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318444-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | MERCK PATENT GMBH (DE) | 2009-12-24 | — | — | US | disclosed |
| WO-2006094604-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | MERCK PATENT GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195965-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | CSNK1A1, MAP3K19, CSNK1E | KDM4E 1799/4885HPGD 217/4885ALDH1A1 1936/4885 |
| US-20090318444-A1 | TETRAHYDRO- AND DIHYDROQUINAZOLINONES | CSNK1A1, MAP3K19, DMPK | KDM4E 1861/4885HPGD 259/4885ALDH1A1 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.